| Trial ID: | L0855 |
| Source ID: | NCT02866214
|
| Associated Drug: |
Febuxostat
|
| Title: |
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Endothelial Dysfunction|Endstage Renal Disease
|
| Interventions: |
DRUG: Febuxostat|DRUG: Placebo
|
| Outcome Measures: |
Primary: Asymmetric Dimethylarginine physiological marker, Asymmetric dimethylarginine (ADMA) physiological marker for assessing endothelial dysfunction will be measured for all the anticipated 50 patients at time zero and by the end of the two months., 2 months | Secondary: Uric Acid , physiological parameter, Uric acid,physiological parameter for assessing the grade of hyperuricemia will be measured for all the anticipated 50 patients at time zero and by the end of the two months., 2 months|High sensitivity C-reactive protein physiological marker, HsCRP , physiological marker for assessing inflammation will be measured for all the anticipated 50 patients at time zero and by the end of the two months., 2 months
|
| Sponsor/Collaborators: |
Sponsor: Ain Shams University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
57
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-08
|
| Completion Date: |
2016-10
|
| Results First Posted: |
|
| Last Update Posted: |
2018-01-02
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT02866214
|
